Xtx Topco LTD Blueprint Medicines Corp Transaction History

Xtx Topco LTD

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 07, 2025	SELL	$86.69 - $115.63 $332,456 - $443,441	-3,835 Reduced 34.41%	7,311 $647,000
Q4 2024 Feb 13, 2025	BUY	$82.48 - $101.39 $737,866 - $907,034	8,946 Added 406.64%	11,146 $972,000
Q3 2024 Nov 14, 2024	SELL	$84.1 - $120.5 $277,866 - $398,132	-3,304 Reduced 60.03%	2,200 $203,000
Q2 2024 Aug 12, 2024	BUY	$85.18 - $108.78 $468,830 - $598,725	5,504 New	5,504 $593,000
Q3 2023 Nov 13, 2023	BUY	$46.9 - $66.0 $227,558 - $320,232	4,852 New	4,852 $243,000

389

66.9M

973K

1.54M

Ticker BPMC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,719,600
Market Cap $7.73B
Description
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...

Get notified when there are updates to the investment portfolio of Xtx Topco LTD, based on Form 13F filings with the SEC.

Stay updated on Xtx Topco LTD with notifications on news.